Home
News
Screeners
Insights
Sunil Healthcare
70.
10
+1.30
(+1.89%)
Market Cap
₹71.89 Cr
PE Ratio
19.65
Industry
Healthcare
Buy
Sell
Company Performance:
1D
+1.89%
1M
-7.68%
6M
+2.64%
1Y
+2.64%
5Y
+2.64%
View Company Insights
Latest news about Sunil Healthcare
Sunil Healthcare declares AGM results; resolutions pass with 99% majority
1 day ago
Sunil Healthcare declared AGM results on September 29, 2026. Resolutions passed with 99.9963% majority in favour. Total votes polled stood at 8,028,728 out of 10,254,750 shares. Only 290 votes cast against both financial adoption and director re-appointment.
Sunil Healthcare sets Sept 21 record date for 52nd AGM
Sep 14, 2026
Sunil Healthcare sets AGM book closure from September 22 to 28, 2026
Sep 03, 2026
Sunil Healthcare Q1 Results: Unaudited financials for Q1FY27 published
Aug 15, 2026
Sunil Healthcare FY26 consolidated profit rises, standalone loss reported
May 31, 2026
More news about Sunil Healthcare
19
May 26
Sunil Healthcare Schedules Board Meeting on May 29, 2026 to Approve Q4 and FY 2025-26 Audited Financial Results
Sunil Healthcare Limited has informed stock exchanges of a Board of Directors meeting to be held on May 29, 2026, via video conferencing, to consider and approve audited standalone and consolidated financial results for Q4 and the full financial year 2025-26 ended March 31, 2026. The meeting is being convened in compliance with Regulation 29 read with Regulation 33 of the SEBI (LODR) Regulations, 2015. The company has also confirmed that the Trading Window under SEBI (Prohibition of Insider Trading) Regulations, 2015, remains closed from April 01, 2026 to May 31, 2026, both days inclusive, as previously intimated on March 27, 2026.
16
Apr 26
Sunil Healthcare Limited Submits SEBI Compliance Certificate for FY 2025-26
Sunil Healthcare Limited filed its SEBI LODR Regulation 40(10) compliance certificate for FY 2025-26 on April 16, 2026. The certificate, verified by ATCS & Associates Practicing Company Secretaries, confirms timely share transfer processes within 15 days of lodgment through RTA Alankit Assignments Limited. Company Secretary Satyendu Patnaik submitted the documentation to BSE and Calcutta Stock Exchange, demonstrating regulatory compliance for the period April 1, 2025 to March 31, 2026.
07
Apr 26
Sunil Healthcare Limited Receives SEBI Compliance Certificate for Q4 FY26
Sunil Healthcare Limited received its quarterly SEBI compliance certificate under Regulation 74(5) for Q4 FY26 ending March 31, 2026. The certificate was issued by RTA Alankit Assignments Limited on April 4, 2026, confirming proper dematerialization procedures for equity shares. Company Secretary Satyendu Pattnaik submitted the certificate to BSE and Calcutta Stock Exchange on April 7, 2026, maintaining regulatory compliance.
06
Feb 26
Sunil Healthcare Limited Announces Q3 FY26 Financial Results
Sunil Healthcare Limited announced its Q3 FY26 financial results showing standalone revenue of ₹2,183.73 lakhs and net profit of ₹44.30 lakhs for the quarter ended December 31, 2025. The consolidated results included foreign subsidiaries with revenue of ₹2,233.49 lakhs and net profit of ₹58.52 lakhs. For nine months, standalone revenue reached ₹6,799.69 lakhs with net profit of ₹151.82 lakhs.
05
Nov 25
Sunil Healthcare Reports Mixed Q2 FY2026 Results with Standalone Profit and Consolidated Loss
Sunil Healthcare Limited announced its Q2 FY2026 results, showing a standalone profit but consolidated loss. Standalone revenue increased to Rs. 235.76 lakhs in Q2, with a profit of Rs. 7.90 lakhs. Half-yearly standalone revenue reached Rs. 461.96 lakhs with a profit of Rs. 50.75 lakhs. However, consolidated operations reported a Q2 loss of Rs. 5.64 lakhs and a half-year loss of Rs. 18.47 lakhs. The Board approved these results on November 4, 2025, with auditors Singhi & Co. conducting a limited review.
Sunil Healthcare
70.
10
+
1.
30
(+
1.
89
%)
1 Year Returns:
+2.64%
Industry Peers
Sun Pharmaceutical
1,800.00
(-
0.
91
%)
Divis Laboratories
9,116.00
(-
1.
89
%)
Torrent Pharmaceuticals
4,752.50
(-
0.
99
%)
Zydus Life Science
1,132.00
(-
2.
58
%)
Cipla
1,340.00
(-
0.
45
%)
Laurus Labs
1,970.70
(-
0.
47
%)
Mankind Pharma
2,499.40
(-
0.
18
%)
Dr Reddys Laboratories
1,209.60
(-
1.
90
%)
Aurobindo Pharma
1,671.10
(-
0.
05
%)
Lupin
2,009.80
(-
1.
00
%)
Get More Market Insights with
Heatmap
FII/DII
Company Filings
MF Holdings
Bulk/ Block Deals
Stock Rental via SLBM
Signals
MTF Insights
F&O Ban - MWPL
Top Deliveries
Market Valuation
IPO
Cyclical Trend
Events Calendar